Business Context and Reporting Period
Company: BIO-RAD LABORATORIES, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: April 15, 2019
Event: Entry into a new Material Definitive Agreement (Revolving Credit Agreement) and termination of the previous agreement.
Key Financial Metrics and Debt Structure
This filing details the restructuring of the Company's credit facilities rather than reporting operational financial results (revenue, profit, or cash flow).
- New Credit Facility: $200,000,000 revolving credit agreement.
- Letters of Credit: Up to $25,000,000 included within the $200 million limit.
- Accordion Feature: Borrowing capacity may be increased by an additional $400,000,000 subject to lender consent.
- Maturity Date: April 15, 2024 (extendable up to three times).
- Interest Rates: LIBOR plus up to 1.750% or Base Rate plus up to 0.750% (margin dependent on leverage ratio).
- Fees: Commitment fee up to 0.250% on unused portion; Letter of Credit fee up to 1.750%.
- Previous Debt: Fully repaid on April 15, 2019, with no penalties incurred.
Material Changes Versus Prior Period
The Company replaced its previous Credit Agreement dated June 20, 2014. The primary changes include:
- Termination: The previous agreement was terminated immediately upon the execution of the new agreement.
- Lenders: The syndicate of lenders has changed, with JPMorgan Chase Bank, N.A. remaining as administrative agent, but with new co-syndication and documentation agents (including MUFG Bank, Ltd., Citibank, N.A., and Wells Fargo Bank, National Association).
- Capacity: The new agreement establishes a $200 million facility with an option to expand to $600 million, whereas the specific capacity of the 2014 agreement is not detailed in this text beyond its termination.
Guidance, Covenants, and Risks
Financial Covenants: The Company must maintain specific ratios tested quarterly (starting Dec 31, 2018):
- Leverage Ratio: Not greater than 3.50 to 1.00.
- Interest Coverage Ratio: Consolidated EBITDA to consolidated interest expense must not be less than 4.00 to 1.00.
Restrictive Covenants: The agreement limits the Company's ability to incur additional debt, make investments, sell assets, create liens, or undergo consolidations/mergers (subject to customary exceptions).
Events of Default: Includes failure to pay principal/interest, covenant breaches, insolvency, bankruptcy, change of control, and failure to pay material judgments. Default allows lenders to accelerate debt.
Use of Proceeds: Permitted acquisitions, working capital, and general corporate purposes.
Investor Verification Checklist
- Verify the Company's current leverage ratio and interest coverage ratio to ensure compliance with the new 3.50:1 and 4.00:1 covenants.
- Confirm the specific interest rate margin currently applicable based on the Company's latest leverage ratio.
- Review the attached Exhibit 10.1 (Credit Agreement) for detailed definitions of "permitted acquisitions" and specific exceptions to restrictive covenants.
- Monitor future filings for any utilization of the $400 million accordion feature to increase borrowing capacity.